All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Completed, but no date, and reported results | 2004-004475-12 | Phase II Clinical Trial ok weekly administration of oxaliplatin plus capecitabine and radioteraphy followed by surgery in patients with resectable locally advanced rectal cancer | bad-data | |
Ongoing, reported early | 2005-003325-67 | Estudio aleatorizado, multicéntrico, fase III, para estudiar la eficacia y seguridad de bevacizumab solo o en combinación con capecitabina y oxaliplatino, como terapia de mantenimiento, tras tratamien... | not-yet-due | |
Ongoing, reported early | 2006-000834-11 | Estudio multicéntrico fase II, abierto, de tratamiento con cetuximab y capecitabina en primera línea de tratamiento en pacientes ancianos con un cáncer colorrectal metastático | not-yet-due | |
Ongoing, reported early | 2006-001880-42 | Estudio piloto fase II abierto, no controlado y multicéntrico para evaluar la eficacia y seguridad de la combinación de cetuximab y quimioterapia (docetaxel, cisplatin, 5-fluorouracilo) como tratamien... | not-yet-due | |
Reported results | 2006-006363-24 | An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer. | 2010-03-30 | due-trials |
Ongoing, reported early | 2006-007062-11 | ESTUDIO FASE II, MULTICÉNTRICO, ABIERTO, NO RANDOMIZADO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CETUXIMAB (ERBITUX®) EN COMBINACIÓN CON OXALIPLATINO Y CAPECITABINA (XELOX) DURANTE 12 SEMANAS SEGUIDO D... | not-yet-due | |
Completed, but no date, and reported results | 2008-001825-32 | "Fase II Docetaxel-Oxiplatino-Capecitabina (DOX) a dosis ajustadas en pacientes con adenocarcinoma gástrico avanzado y estado general subóptimo" | bad-data | |
Completed, but no date, and reported results | 2008-004688-20 | Estudio de fase II con una combinación de Irinotecán, Capecitabina (Xeloda®) y Bevacizumab (Avastin®) en cáncer colorrectal metastático no pretratado | bad-data | |
Ongoing, reported early | 2008-006766-28 | Estudio de fase II exploratorio, abierto, aleatorizado, multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con quimioterapia FOLFOX 4 o panitumumab con quimioterapia F... | not-yet-due | |
Completed, but no date, and reported results | 2009-010192-24 | Estudio fase II randomizado de Capecitabina + Bevacizumab versus Capecitabina + Oxaliplatino + Bevacizumab en combinación con radioterapia externa como tratamiento preoperatorio en pacientes con cánce... | bad-data | |
Completed, but no date, and reported results | 2009-010833-27 | Estudio de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con irinotecán en pacientes con cáncer colorrectal metastásico con KRAS no mutado y re... | bad-data | |
Ongoing, reported early | 2009-012562-31 | Tratamiento selectivo en cáncer colorrectal: selección de capecitabina o 5-fluorouracilo para ser combinados con oxaliplatino o irinotecan como quimioterapia en combinación con bevacizumab en primera... | not-yet-due | |
Completed, but no date, and reported results | 2009-016661-28 | Estudio de fase II de panitumumab como agente único de primera línea en pacientes ancianos frágiles con cáncer colorrectal avanzado con KRAS no mutado | bad-data | |
Ongoing, reported early | 2009-017194-38 | Estudio piloto fase II aleatorizado, multicentrico para evaluar la seguridad y eficacia del tratamiento de mFOLFOX-6 mas cetuximab frente a un tratamiento inicial con mFOLFOX-6 mas cetuximab (por 8 ci... | not-yet-due | |
Completed, but no date, and reported results | 2010-022599-30 | ENSAYO fase IIb randomizado para evaluar la eficacia de Gemcitabina-Erlotinib vs Gemcitabina- Erlotinib-Capecitabina en pacientes con cáncer de páncreas metastásico. | bad-data | |
Ongoing, reported early | 2011-002384-16 | A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma. | not-yet-due | |
Completed, but no date | 2012-000846-37 | Phase III, randomized clinical trial to evaluate FOLFOX + bebacizumab versus FOLFOXIRI + bebacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and wi... | bad-data | |
Reported results | 2012-001955-38 | Open label Phase II study of Folfiri + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinoteca... | 2016-07-30 | due-trials |
Completed, but no date, and reported results | 2013-000236-94 | Phase II study of Regorafenib as a single agent for first-line treatment of patients with metastatic colorectal cancer (MCRC) who are fragile and/or not candidates for polychemotherapy | bad-data | |
Completed, but no date, and reported results | 2014-000703-26 | Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer (mCRC) with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab. | bad-data | |
Exempt | 2014-005350-19 | A phase I/II study of nab-paclitaxel (Abraxane®) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma | not-yet-due | |
Reported results | 2016-000640-34 | A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients | 2018-09-24 | due-trials |
Reported results | 2016-001508-45 | Phase II clinical trial to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphisms | 2018-12-11 | due-trials |
Ongoing | 2016-004076-21 | Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by ... | not-yet-due | |
Ongoing | 2018-000347-60 | Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panit... | not-yet-due |